Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adults
Shots:
- The US FDA has granted approval to Zepbound for treating moderate-to-severe obstructive sleep apnea (OSA) among obese adults, based on P-III (SURMOUNT-OSA) studies
- The P-III trial assessed safety & efficacy of Zepbound vs PBO for treating adults (n=469) with moderate-to-severe OSA & obesity not using positive airway pressure (PAP) therapy in Study 1 and those who continued PAP therapy in Study 2
- Zepbound significantly reduced breathing disruptions in OSA patients, with 25 vs 5 fewer events per hour off PAP & 29 vs 6 fewer on PAP; remission/mild OSA occurred in 42% (no PAP) & 50% (with PAP) vs 16% & 14% post 1yr. A weight loss of 18% (no PAP) & 20% (on PAP) vs 2% with PBO
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports Kinsula (Donanemab-Azbt) Approval in China to Treat Early Symptomatic Alzheimer's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
